News and Trends 2 May 2017
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing "off-the-shelf" therapies, based on…